Xspray Pharma Q2 2025 - Case defining months ahead

Redeye provides an update on Xspray following its Q2 report. The company faces two near-term material events: the NDA submission of its nilotinib candidate, XS003, and the PDUFA date for its lead candidate, Dasynoc, in October, offering opportunities for near-term share price-supportive newsflow.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/